One such strategy involves genetically engineered T cells, known as chimeric antigen receptor T (CAR-T) cells, designed to specifically target MSLN—an antigen found mainly, although not exclusively, in mesothelioma cells [110,111,112]. The gene discussed is MSLN; the disease is mesothelioma.